Geode Capital Management LLC Purchases 21,183 Shares of Enfusion, Inc. (NYSE:ENFN)

Geode Capital Management LLC increased its position in Enfusion, Inc. (NYSE:ENFN) by 2.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 1,050,549 shares of the company’s stock after buying an additional 21,183 shares during the period. Geode Capital Management LLC owned about 0.82% of Enfusion worth $10,823,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the business. New York State Common Retirement Fund lifted its holdings in shares of Enfusion by 23.8% in the fourth quarter. New York State Common Retirement Fund now owns 1,926,968 shares of the company’s stock worth $19,848,000 after buying an additional 370,498 shares in the last quarter. Wellington Management Group LLP increased its holdings in Enfusion by 6.1% in the 4th quarter. Wellington Management Group LLP now owns 1,035,996 shares of the company’s stock valued at $10,671,000 after acquiring an additional 59,700 shares during the last quarter. State Street Corp lifted its stake in Enfusion by 2.3% in the 3rd quarter. State Street Corp now owns 952,895 shares of the company’s stock worth $9,043,000 after purchasing an additional 21,729 shares in the last quarter. Impax Asset Management Group plc boosted its holdings in shares of Enfusion by 31.5% during the 4th quarter. Impax Asset Management Group plc now owns 890,000 shares of the company’s stock valued at $9,167,000 after purchasing an additional 213,052 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Enfusion by 1.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 371,151 shares of the company’s stock valued at $3,823,000 after purchasing an additional 5,639 shares in the last quarter. Hedge funds and other institutional investors own 81.05% of the company’s stock.

Enfusion Stock Up 0.5 %

Shares of NYSE:ENFN opened at $10.85 on Wednesday. The firm has a fifty day simple moving average of $11.07 and a two-hundred day simple moving average of $10.45. The stock has a market capitalization of $1.40 billion, a P/E ratio of 271.29, a PEG ratio of 1.85 and a beta of 0.92. Enfusion, Inc. has a 52 week low of $7.83 and a 52 week high of $11.80.

Enfusion (NYSE:ENFN) last issued its quarterly earnings data on Monday, March 3rd. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.02). The company had revenue of $52.94 million for the quarter, compared to the consensus estimate of $53.98 million. Enfusion had a return on equity of 6.67% and a net margin of 1.70%. On average, analysts expect that Enfusion, Inc. will post 0.06 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, William Blair reiterated a “market perform” rating on shares of Enfusion in a research report on Monday, January 13th.

Insider Buying and Selling

In other news, CEO Oleg Movchan sold 11,452 shares of the stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $11.39, for a total value of $130,438.28. Following the sale, the chief executive officer now directly owns 631,847 shares in the company, valued at approximately $7,196,737.33. This represents a 1.78 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Bradley Herring sold 4,645 shares of the business’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $11.38, for a total value of $52,860.10. Following the transaction, the chief financial officer now owns 324,689 shares of the company’s stock, valued at approximately $3,694,960.82. The trade was a 1.41 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 66,223 shares of company stock worth $754,778 over the last three months. 36.44% of the stock is owned by insiders.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.